Hydroxychloroquine (All indications except Antiphospholipid Syndrom) updated on 10-07-2022

Neonatal death (< 28 days of life)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13773
R53897		 Baalbaki, 2020 Neonatal death (NOS) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indication HCQ: Systemic lupus erythematosus (SLE) 0.63 [0.04;10.48] C 1/47   1/30 2 47
ref
S13700
R53339		 Al Arfaj, 2010 Neonatal deaths (NOS) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indication HCQ: Systemic lupus erythematosus (SLE) 0.64 [0.03;13.51] C 0/69   2/222 2 69
ref
S13661
R53056		 Levy, 2001 Newborn died (NOS) 2nd and/or 3rd trimester randomized controlled trial unexposed, sick Adjustment: Randomisation Indication HCQ: Systemic lupus erythematosus (SLE) 0.30 [0.01;8.35] C 0/10   1/10 1 10
ref
S13701
R53347		 Buchanan, 1996 Neonatal death (NOS) during pregnancy (anytime or not specified) retrospective cohort unexposed, sick Adjustment: No Indication HCQ: Systemic lupus erythematosus (SLE) 2.97 [0.26;34.24] C 2/31   1/44 3 31
ref
Total 4 studies 0.93 [0.22;3.89] 8 157
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Baalbaki, 2020Baalbaki, 2020 0.63[0.04; 10.48]24726%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Al Arfaj, 2010Al Arfaj, 2010 0.64[0.03; 13.51]26922%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Levy, 2001Levy, 2001 0.30[0.01; 8.35]11018%ROB confusion: lowROB selection: lowROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Buchanan, 1996Buchanan, 1996 2.97[0.26; 34.24]33134%ROB confusion: criticalROB selection: unclearROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (4 studies) I2 = 0% 0.93[0.22; 3.89]81570.210.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.21[0.25; 5.85]71470%NABaalbaki, 2020 Al Arfaj, 2010 Buchanan, 1996 3 case control studiescase control studies 0 RCTRCT 0.30[0.01; 8.35]110 -NALevy, 2001 1 Type of controls unexposed, sickunexposed, sick 0.93[0.22; 3.89]81570%NABaalbaki, 2020 Al Arfaj, 2010 Levy, 2001 Buchanan, 1996 4 Tags Adjustment   - No  - No 1.21[0.25; 5.85]71470%NABaalbaki, 2020 Al Arfaj, 2010 Buchanan, 1996 3   - Randomisation  - Randomisation 0.30[0.01; 8.35]110 -NALevy, 2001 1 Indication HCQ   - Systemic lupus erythematosus (SLE)  - Systemic lupus erythematosus (SLE) 0.93[0.22; 3.89]81570%NABaalbaki, 2020 Al Arfaj, 2010 Levy, 2001 Buchanan, 1996 4 All studiesAll studies 0.93[0.22; 3.89]81570%NABaalbaki, 2020 Al Arfaj, 2010 Levy, 2001 Buchanan, 1996 40.110.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-4.03.92.0400.000Baalbaki, 2020Al Arfaj, 2010Levy, 2001Buchanan, 1996

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 0.93[0.22; 3.89]81570%NABaalbaki, 2020 Al Arfaj, 2010 Levy, 2001 Buchanan, 1996 40.510.01.0